Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Oscar Health Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Oscar Health Inc trades at $28.73 (market cap $8.63B). The key difference: Oscar Health Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Oscar Health Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | OSCR | |
|---|---|---|
Market Cap | $5.07B | $8.63B |
Sector | Health | Health |
52-Week High | $29.41 | $32.18 |
52-Week Low | $20.06 | $10.85 |
Enterprise Value | $4.19B | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
OSCR trades at $27.97, up 1.08% today, with a bearish technical signal but strong recent earnings beats in Q1 and Q2 2026. The company reported record profitability and raised its full-year outlook, driven by membership growth and cost controls. Key support lies at $26, with resistance at $28. Revenue surged 70% year-over-year in H1 2026 to $4.9 billion, per PYMNTS on August 6, 2026.
Outlook is positive due to robust growth and margin expansion, but risks include execution challenges and competitive pressures. Analysts have a consensus price target of $32.50, with 27% buy ratings. The stock offers value with a P/S of 0.53, though net income volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
